CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1483-1487

  Hennessy, Sean ^a   Leonard, Charles E ^a   Freeman, Cristin P ^a   Metlay, Joshua P ^a,b   Xin Chu, ^c   Strom, Brian L ^a   Bilker, Warren B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WEIS CENTER FOR RESEARCH   (United States)

Author keywords

ABCB1 protein; Cytochrome P 450 CYP2C19; Cytochrome P 450 CYP2C9; Human; P glycoprotein; Pharmacogenetics; Phenytoin

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MULTIDRUG RESISTANCE PROTEIN 1; PHENYTOIN;

ACUTE TOXICITY; AGED; ARTICLE; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOSPITALIZATION; HUMAN; MALE; NEUROTOXICITY;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; DNA; FEMALE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HOSPITALIZATION; HUMANS; MALE; MOUTH MUCOSA; P-GLYCOPROTEIN; PHENYTOIN; POLYMERASE CHAIN REACTION; RISK;

EID: 71449105222     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009343006     Document Type: Article

References (18)

1. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol. 1991 ; 31 (2). 125-130.
2. Luna-Tortós C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 ; 55 (8). 1364-1375.
3. Schinkel AH, Wagenaar E., Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 ; 97 (11). 2517-2524.
4. Tishler DM, Weinberg KI, Hinton DR, Barbaro N., Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995 ; 36 (1). 1-6.
5. Rivers F., OBrien TJ, Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur J Pharmacol. 2008 ; 598 (1-3). 1-8.
6. Baltes S., Gasten AM, Fedrowitz M., Potschka H., Kaever V., Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 ; 52 (2). 333-346. 7.
7. Crowe A., Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target. 2006 ; 14 (5). 291-300.
8. Kerb R., Aynacioglu AS, Brockmöller J., et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001 ; 1 (3). 204-210.
9. Tate S., Depondt C., Sisodiya S., et al. Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA. 2005 ; 102 (15). 5507-5512.
10. van der Weide J., Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001 ; 11 (4). 287-291.
11. Yukawa E., Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther. 2006 ; 31 (3). 275-282.
12. Metlay JP, Cohen A., Polsky D., Kimmel SE, Koppel R., Hennessy S. Medication safety in older adults: home-based practice patterns. J Am Geriatr Soc. 2005 ; 53 (6). 976-982.
13. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 ; 6 (4). 341-349.
14. Kidd RS, Curry TB, Gallagher S., Edeki T., Blaisdell J., Goldstein JA Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 ; 11 (9). 803-808.
15. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001 ; 70 (2). 189-199.
16. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 ; 11 (2). 116-128.
17. Agency for Healthcare Research and Quality. HCUPnet: Healthcare Cost and Utilization Project. Rockville, MD: Agency for Healthcare Research and Quality ; 2008.
18. Leonard CE, Haynes K., Localio AR, et al. Diagnostic E-codes for commonly-used, narrow therapeutic index medications poorly predict adverse drug events. J Clin Epidemiol. 2008 ; 61 (6). 561-571.